Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

By M. Middleton, J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates and 9 more. Journal of Clinical Oncology, 2000

1,243 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4c79577f6a3cfa6b791ee8be5d2b784641cb5c2c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. S. Rosenberg
2. N. Restifo
3. M. Dudley
4. T. Schatton
5. M. Frank
6. N. Frank

In Oncology

1. S. Rosenberg
2. N. Restifo
3. M. Dudley
4. Jie Yang
5. R. Sherry
6. U. Kammula
7. M. Hughes
8. J. Wunderlich

Citations in the corpus

• ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. (2005, background): “Chemoresistance in malignant melanoma for agents currently in clinical use for this malignancy, such as dacarbazine and temozolamide (26, 27), is mediated by molecular mechanisms, such as increased cellular sulfhydryls, altered signal transduction, and increased DNA repair (28).”
• Temozolomide and treatment of malignant glioma. (2000, background): “in 305 patients with advanced metastatic melanoma (95).”
• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011, neutral): “Arthralgia Grade 2 60 (18) 1 (<1) Grade 3 11 (3) 2 (<1) Rash Grade 2 33 (10) 0 Grade 3 28 (8) 0 Fatigue Grade 2 38 (11) 33 (12) Grade 3 6 (2) 5 (2) Cutaneous squamous-cell carcinoma‡ Grade 3 40 (12) 1 (<1) Keratoacanthoma§ Grade 2 7 (2) 0 Grade 3 20 (6) 0 Nausea Grade 2 25 (7) 32 (11) Grade 3 4 (1) ”
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011, background): “Durable complete regressions using dacarbazine, the only other FDA-approved treatment for melanoma, is seen in less than 1% of patients (1, 2).”